263 related articles for article (PubMed ID: 38199897)
1. Bispecific Antibodies in the Treatment of Multiple Myeloma.
Zhou X; Xiao X; Kortuem KM; Einsele H
Hematol Oncol Clin North Am; 2024 Apr; 38(2):361-381. PubMed ID: 38199897
[TBL] [Abstract][Full Text] [Related]
2. Practical Aspects of Immunotherapy: A Report from the 20th International Myeloma Society (IMS) Annual Meeting.
Raje NS; Cohen AD; Patel KK; van de Donk NWCJ; Richter J; San-Miguel J
Clin Lymphoma Myeloma Leuk; 2024 Jun; 24(6):350-357. PubMed ID: 38627181
[TBL] [Abstract][Full Text] [Related]
3. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
Cho SF; Anderson KC; Tai YT
Front Immunol; 2018; 9():1821. PubMed ID: 30147690
[TBL] [Abstract][Full Text] [Related]
4. Impact of Treatment Modality and Route of Administration on Cytokine Release Syndrome in Relapsed or Refractory Multiple Myeloma: A Meta-Analysis.
Soltantabar P; Sharma S; Wang D; Lon HK; Czibere A; Hickmann A; Elmeliegy M
Clin Pharmacol Ther; 2024 Jun; 115(6):1258-1268. PubMed ID: 38459622
[TBL] [Abstract][Full Text] [Related]
5. BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice.
Zhou X; Rasche L; Kortüm KM; Mersi J; Einsele H
Haematologica; 2023 Apr; 108(4):958-968. PubMed ID: 36263838
[TBL] [Abstract][Full Text] [Related]
6. Chimeric antigen receptor T-cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: An update.
Lakshman A; Kumar SK
Am J Hematol; 2022 Jan; 97(1):99-118. PubMed ID: 34661922
[TBL] [Abstract][Full Text] [Related]
7. T cell redirecting bispecific antibodies for multiple myeloma: emerging therapeutic strategies in a changing treatment landscape.
Kazandjian D; Kowalski A; Landgren O
Leuk Lymphoma; 2022 Dec; 63(13):3032-3043. PubMed ID: 36059239
[TBL] [Abstract][Full Text] [Related]
8. Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapy in Multiple Myeloma: Moving Into the Future.
Holstein SA; Grant SJ; Wildes TM
J Clin Oncol; 2023 Sep; 41(27):4416-4429. PubMed ID: 37471687
[TBL] [Abstract][Full Text] [Related]
9. Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma.
Tacchetti P; Talarico M; Barbato S; Pantani L; Mancuso K; Rizzello I; Zamagni E; Cavo M
Expert Rev Anticancer Ther; 2024 Jun; 24(6):379-395. PubMed ID: 38798125
[TBL] [Abstract][Full Text] [Related]
10. Chimeric antigen receptor and bispecific T-cell engager therapies in multiple myeloma patients with prior allogeneic transplantation.
Hammons L; Haider S; Portuguese AJ; Banerjee R; Szabo A; Pasquini M; Chhabra S; Radhakrishnan S; Mohan M; Narra R; Dong J; Janz S; Shah NN; Hamadani M; D'Souza A; Hari P; Dhakal B
Br J Haematol; 2024 Mar; 204(3):887-891. PubMed ID: 38054558
[TBL] [Abstract][Full Text] [Related]
11. Focus on monoclonal antibodies targeting B-cell maturation antigen (BCMA) in multiple myeloma: update 2021.
Demel I; Bago JR; Hajek R; Jelinek T
Br J Haematol; 2021 May; 193(4):705-722. PubMed ID: 33216972
[TBL] [Abstract][Full Text] [Related]
12. Integrating Immune Therapies for the Treatment of Multiple Myeloma.
Mikkilineni L; Sidana S
J Natl Compr Canc Netw; 2023 Dec; 21(12):1303-1311. PubMed ID: 38081142
[TBL] [Abstract][Full Text] [Related]
13. Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast.
Landgren O; Nadeem O
Adv Ther; 2023 Aug; 40(8):3291-3303. PubMed ID: 37328635
[TBL] [Abstract][Full Text] [Related]
14. Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas.
Trabolsi A; Arumov A; Schatz JH
Blood Cancer J; 2024 Feb; 14(1):27. PubMed ID: 38331870
[TBL] [Abstract][Full Text] [Related]
15. Relapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: first reported case.
Mutlu YG; Yıgıt Kaya S; Maral S; Melek E; Baslar Z; Kaynar L; Sevindik OG
Front Immunol; 2023; 14():1276295. PubMed ID: 37901215
[TBL] [Abstract][Full Text] [Related]
16. "Off-the-shelf" immunotherapies for multiple myeloma.
Mohammed T; Mailankody S
Semin Oncol; 2022 Feb; 49(1):60-68. PubMed ID: 35123801
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy in multiple myeloma.
Asensi Cantó P; Arnao Herraiz M; de la Rubia Comos J
Med Clin (Barc); 2024 May; 162(10):485-493. PubMed ID: 38218655
[TBL] [Abstract][Full Text] [Related]
18. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma.
Mei H; Li C; Jiang H; Zhao X; Huang Z; Jin D; Guo T; Kou H; Liu L; Tang L; Yin P; Wang Z; Ai L; Ke S; Xia Y; Deng J; Chen L; Cai L; Sun C; Xia L; Hua G; Hu Y
J Hematol Oncol; 2021 Oct; 14(1):161. PubMed ID: 34627333
[TBL] [Abstract][Full Text] [Related]
19. Chimeric antigen receptor T-cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice.
Parikh RH; Lonial S
CA Cancer J Clin; 2023; 73(3):275-285. PubMed ID: 36627265
[TBL] [Abstract][Full Text] [Related]
20. Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond.
Su CT; Ye JC
J Hematol Oncol; 2021 Jul; 14(1):115. PubMed ID: 34301270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
